Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2023Advances in TherapyOpen Access

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

CPChristopher ParkerRoyal Marsden NHS Foundation Trust
Fei‐Fei Liu
Fei‐Fei LiuJiangsu Hengrui Medicine (China)KDKristen A. DegerIthaka Harbors

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Parker et al. (2023) studied this question.

synapsesocial.com/papers/6a1542809b87f33fc69f62c3https://doi.org/10.1007/s12325-023-02444-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Management of relapsed-refractory diffuse large B cell lymphoma2014 · 77 citations
  2. 2Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial2020 · 31 citations
  3. 3Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases2013 · 38 citations
  4. 4Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)2021 · 58 citations
  5. 5CAR T-Cell Therapy: Adverse Events and Management2019 · 83 citations